萊茵生物(002166.SZ):預計2024年全年營收增速為15%-20%
格隆匯4月17日丨萊茵生物(002166.SZ)於2024年04月15日進行線上交流,就“根據公司以往的財務數據分析,12%是公司的淨利潤率中樞,想請問公司淨利潤預計多久能修復到這個水平?”,公司回覆稱,根據目前業務發展情況來看,公司預計2024年全年營收增速為15%-20%,主營業務的淨利潤預計能實現翻番以上,儘管今年公司在費用方面會有些變化,新工廠投產會帶來部分固定資產折舊費用的增長,以及本年度公司在人才引進和市場開發方面的投入預計將有所增加,但我們認為2024年淨利潤率就有望修復到往年平均水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.